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Abstract
The members of the Bcl-2 family of proteins are crucial regulators of apoptosis. In order to determine cell fate, these proteins must be
targeted to distinct intracellular membranes, including the mitochondrial outer membrane (MOM), the membrane of the endoplasmic
reticulum (ER) and its associated nuclear envelope. The targeting sequences and mechanisms that mediate the specificity of these proteins for
a particular cellular membrane remain poorly defined. Several Bcl-2 family members have been reported to be tail-anchored via their
predicted hydrophobic COOH-terminal transmembrane domains (TMDs). Tail-anchoring imposes a posttranslational mechanism of
membrane insertion on the already folded protein, suggesting that the transient binding of cytosolic chaperone proteins to the hydrophobic
TMD may be an important regulatory event in the targeting process. The TMD of certain family members is initially concealed and only
becomes available for targeting and membrane insertion in response to apoptotic stimuli. These proteins either undergo a conformational
change, posttranslational modification or a combination of these events enabling them to translocate to sites at which they are functional.
Some Bcl-2 family members lack a TMD, but nevertheless localize to the MOM or the ER membrane during apoptosis where they execute
their functions. In this review, we will focus on the intracellular targeting of Bcl-2 family members and the mechanisms by which they
translocate to their sites of action. Furthermore, we will discuss the posttranslational modifications which regulate these events.
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1. Membrane association via COOH-terminal anchors
(tail-anchoring)
1.1. General mechanisms of tail-anchoring into the
membrane of the endoplasmic reticulum (ER) and/or the
mitochondrial outer membrane (MOM)
Apoptosis is a tightly regulated physiological process
with important implications during development and in the
progression of disease. The Bcl-2 family of proteins are
important regulators of apoptosis in mammalian cells [1,2].
There is growing evidence indicating that all of the members
recognized so far act exclusively on the cytoplasmic face of
mitochondria and/or the ER. Many of the Bcl-2 family
proteins are tail-anchored to these membranes via a hydro-
phobic COOH-terminal transmembrane domain (TMD)
[3,4]. The members carrying a COOH-terminal TMD belong
to a growing class of tail-anchored proteins, which include a
variety of proteins that have different functions (for review
see Ref. [3]). Tail-anchored proteins are specifically targeted
to and inserted into either the MOM or the ER membrane via
the hydrophobic TMD, which varies in length between 15
and 22 aa and is suggested to span the membrane once in an
a-helical conformation [3,5]. Once inserted into the mem-
brane, the N-terminal bulk of the protein faces the cytosol.
Tail-anchoring therefore imposes a posttranslational mecha-
nism of membrane insertion on these proteins as the N-
terminal bulk of the protein is folded before the hydrophobic
COOH-terminus is released from the ribosome. The release
of this hydrophobic sequence implies a requirement for
mechanisms that prevent aggregation, such as the presence
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of cytosolic chaperone proteins or translation within the
vicinity of the membrane. Several interactions with molec-
ular chaperones or other cytoplasmic factors have been
described for the delivery of nuclear encoded polypeptides
to the MOM, which may also be required for the targeting of
tail-anchored proteins [6].
Little is known about the targeting signals and mecha-
nisms by which tail-anchored proteins reach their final
destination. Much of the research on tail-anchoring is
derived from studies in yeast in which 55 tail-anchored
proteins were identified in a recent sequence analysis study
[7]. The vast majority of the proteins studied, including
several SNARE proteins, are initially targeted to the ER and
only six proteins, including the trans outer membrane
proteins TOM-5, -6, -7 and -22 are targeted directly to the
MOM [7–12]. The mechanisms of targeting of the mam-
malian VAMP/SNARE proteins, the two isoforms of cyto-
chrome b5 (ER-specific and MOM-specific cyt.b5) and
the Bcl-2 family members have also been investigated
[5,11–21]. Among these studies, saturable, ATP- and re-
ceptor-dependent, as well as non-saturable, ATP- and re-
ceptor-independent mechanisms have been described using
in vitro assays.
A common feature of tail-anchored proteins is that all of
the necessary targeting information is located in, directly up-
or downstream of the TMD itself. Generally, the COOH-
terminal stretch of the protein, which includes the TMD and
its flanking residues, is sufficient for the insertion of a
reporter protein into the membrane with the same specificity
and stability as the wild-type protein. Recent reports have
highlighted the role of the flanking regions in defining the
membrane-specificity of the protein [8,12,22]. Investigations
of the targeting mechanisms of the TOM-proteins in yeast
have determined that both the internal characteristics of the
TMD (mainly its hydrophobicity) as well as the basicity of
the flanking regions are required for specific MOM- or ER-
targeting [8]. Highly hydrophobic TMDs (e.g. as calculated
using the algorithm of Kyte and Doolittle [23]) direct the
protein to the ER whereas less hydrophobic TMDs show a
higher tendency for the MOM. Additionally, the presence of
basic aa downstream of the TMD increases the specificity for
the MOM [8]. The recent resolution of the three-dimensional
structure of TOM-20 has determined its affinity for the
hydrophobic face of the amphipathic signal sequence of
proteins to be imported into the mitochondrial matrix or to
be inserted into the inner mitochondrial membrane. In
contrast, the associated TOM-22 receptor has been reported
to display a preference for the hydrophilic face of these
signal sequences [10,24,25]. For the above-mentioned rea-
sons, TOM-20 may also act as a receptor for MOM-targeted
tail-anchored proteins, although as yet unidentified receptors
may also play a role [7,11,26]. Recent evidence for a role of
the TOM complex as a receptor for Bcl-2 family members is
derived from an in vitro study describing the insertion of Bcl-
2 into the yeast MOM. This study reports the involvement of
a TOM-22-independent interaction of the hydrophobic TMD
of Bcl-2 with TOM-20. Interestingly, this interaction is
dependent on the presence of two positively charged ly-
sine-residues flanking the TMD of Bcl-2 [27].
The mechanisms by which putative receptors on the ER
recognize the signal sequences of tail-anchored proteins and
mediate their membrane insertion are not well understood.
One of the best candidates is the posttranslational Sec-
machinery; however, the exact composition of the complex
as well as the mechanisms by which it interacts with the
TMD of targeted proteins remain unclear [28–33]. Fur-
thermore, Sec-independent mechanisms mediating ER-
membrane tail-anchoring have been implicated in these
processes [34].
1.2. Organelle specificity of the various Bcl-2 family
members
Bcl-2 family members that have a COOH-terminal hy-
drophobic TMD are targeted to the appropriate membrane
either immediately following their synthesis or in response
to an apoptotic stimulus. It is believed that the main function
of these proteins is restricted to these sites within the cell
[1,2]. It has been suggested that the anti-apoptotic Bcl-2
family members, such as Bcl-2, Bcl-xL, Bcl-w and Mcl-1,
reside on several intracellular membranes in order to control
apoptosis. Whilst the majority of endogenous Bcl-2 (about
two thirds) is located on the ER membrane and associated
nuclear envelope, the remaining fraction (about one third) is
located on the MOM [19,35–37]. Supporting evidence
comes from a study in which GFP fused to the last 39 aa
of Bcl-2 is mainly located on the ER membranes when
overexpressed in yeast. In a similar fashion, the MOM
protein TOM-22 is redirected to the ER when carrying the
last 33 aa of Bcl-2 [12]. Bcl-2 differs from its ‘‘colleagues’’
in that it is always integrally inserted into membranes,
whereas Bcl-xL and Bcl-w are both found in a soluble,
loosely attached form as well as an integrally membrane-
inserted protein [16,22,38–40].
In contrast to Bcl-2, Bcl-xL shows high specificity for the
MOM, which may be also true for other Bcl-2 family
members such as Bcl-B and Bcl-w [22,41]. When compar-
ing the TMDs of Bcl-2 and Bcl-xL, no obvious differences
in length (19 aa for both) or in mean hydrophobicity
(hydropathy scores were calculated using the algorithm of
Kyte and Doolittle, as reported by Beilharz et al. [7]) were
detected (Fig. 1a). However, some tendencies can be ob-
served when looking at the shape of the hydropathy plots.
MOM-targeted proteins such as Bcl-xL, myxoma virus
M11L protein, hNIP3 and hNIPL all show a similar plot
with an increased hydrophobicity in the C-terminal half of
their TMD (Fig. 1d). This also holds true for three of the
four tail-anchored TOM-proteins in yeast (TOM-5, -6, -7,
-22), in which only the TMD of TOM-5 differs in the shape
of its plot (Fig. 1c). On the other hand, proteins that are also
targeted to the ER/nuclear envelope, such as Bcl-2 and Mcl-
1, are more hydrophobic in the N-terminal half of their
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TMDs (Fig. 1b). However, there are exceptions to this
‘‘rule’’ and it remains to be determined whether the hydro-
phobic character and distribution of hydrophobic residues
within the TMD play an important role in targeting speci-
ficity. Taken together, it is rather unlikely that the hydro-
phobicity of the TMD is the only determinant for ER- or
MOM-specific targeting in these proteins.
There are, however, indications that the flanking regions,
and especially the number of positively charged residues
(arginine and lysine), play an important role in the membrane
specific targeting of tail-anchored proteins. High basicity
surrounding the TMD usually leads to a more MOM-specific
targeting, whereas TMDs surrounded by fewer basic resi-
dues have a higher tendency to be targeted to the ER-
membrane. This observation also holds true for tail-anchored
proteins other than Bcl-2 family members [8,17,22,42]. Bcl-
2 can be specifically targeted to the MOM by increasing the
net positive charge at the very COOH-terminus of the
protein. Furthermore, a decrease in the number of basic
residues at the very COOH-terminus in Bcl-xL or in a
GFP-TOM-5 fusion protein causes a marked decrease in
MOM-specificity, leading to an accumulation of these pro-
teins on the ER-/nuclear outer membrane. These experiments
also support the idea that the TMD itself does not solely
determine the membrane specificity. Furthermore, whilst the
number of basic charges is critical, the nature of the basic
residues as well as the spacing between them do not appear
to be relevant (Lys can be exchanged by Arg and vice versa
without diminishing the specificity and efficiency of target-
ing) (Refs. [8,22], and own unpublished observations).
There is yet little published data describing cytosolic
binding proteins or putative membrane receptors for the
antiapoptotic Bcl-2 family members. One very recent paper
by Shirane and Nakayama [43] shows that the mitochondrial
FK506-binding protein 38 (FKBP38) interacts with both
Bcl-2 and Bcl-xL and may play an important role in
targeting these proteins to the mitochondrial membrane.
FKBP38 would therefore act as a mitochondrial receptor
for Bcl-2 and Bcl-xL, probably by associating with members
of the TOM machinery [44]. However, these findings do not
explain how and why Bcl-2 also localizes to the ER- and
nuclear outer membrane.
The Bax-like proapoptotic members (Bax, Bak and Bok)
were initially described to be targeted to the MOM where
Fig. 1. Differences between MOM- and ER-specific tail-anchored proteins in the hydrophobic distribution within the TMD. Hydropathy plots of the TMDs of
several tail-anchored proteins. Amino acids are represented on the X-axis, the relative hydrophobic score on the Y-axis. Hydrophobicity analysis was performed
as described in Beilharz et al. [7], using the ProtScale site at http://www.expasy.org/cgi-bin/protscale.pl. Scores were obtained by applying the Kyte and
Doolittle algorithm on the TMD sequence (22 aa) using a window size of 5 aa. (a) Although the mean hydrophobicity of the TMDs does not significantly differ,
the TMD of the specifically MOM-targeted Bcl-xL shows another plot shape than the one from the ER/MOM targeted Bcl-2. (b) Similar plots for ER/MOM
targeted Bcl-2 and Mcl-1. (c) The TMDs of TOM-6, -7 and -22 look similar to Bcl-xL, TOM-5 being an exception. (d) Other MOM-specific proteins (M11L,
NIPL and NIP3) have also a TMD with a similar plot shape as for Bcl-xL. (e) The hydropathy plots for the TMDs of Bax and Bak look similar.
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they are thought to exert their function. Recently, ER-
localization and, in consequence, ER-specific functions have
been reported for these proteins [4,45,46]. Most of the
targeting studies have been performed in vitro or on over-
expressed proteins. In addition to its membrane attached
form, Bax is found up to 60% as a soluble protein in the
cytosol in healthy cells and it is proposed to translocate to
and insert into the MOM during apoptosis [39,47]. The
possible mechanisms by which Bax translocation occurs
are discussed below. In contrast to Bax, Bak is inserted into
the MOM and to a lesser extent into the ER membrane.
When comparing the hydropathy plots of the TMDs of Bax
and Bak, a similar curve is seen (which interestingly differs
from those of Bcl-xL, M11L, hNIP3 and hNIPL), supporting
the concept that they are both targeted to and functional on
the same intracellular membranes (Fig. 1e) [1].
2. Translocation of Bcl-2 family members to intracellular
membranes during the onset of apoptosis
Although some Bcl-2 family members are targeted direct-
ly to the membrane on which they execute their function via
specific targeting sequences, others require a secondary level
of regulation allowing them to translocate in response to an
apoptotic stimulus. This secondary level of regulation may
act as a ‘safety switch’ preventing premature activation or
inactivation of these proteins. Translocation is initiated by a
variety of mechanisms, which include transcriptional regula-
tion, posttranslational modification and/or conformational
change [2,48,49]. In the case of the multidomain Bcl-2 family
members Bax and Bcl-w, their TMDs are folded back into a
hydrophobic pocket formed by the protein [40,50,51]. In
response to an apoptotic stimulus, the TMD has been sug-
gested to become available for MOM targeting and/or inser-
tion. Several BH3-only proteins are sequestered to subcellu-
lar locations other than those on which they function and
require modification before they can translocate to the mito-
chondria where they interact with multidomain Bcl-2 family
members. Whilst Bid requires proteolytic cleavage to expose
residues that are subsequently modified to allow its translo-
cation, BH3-only proteins such as Bad, Bmf and Bim are
sequestered by binding proteins and translocate to the mito-
chondria following specific apoptotic stimuli (Fig. 2). Certain
BH3-only proteins including Bik, Hrk, Blk, and Bim have
TMDs, which may become exposed and available for target-
Fig. 2. Posttranslational modification is required for the translocation of certain multidomain and BH3-only Bcl-2 family members, whilst some proteins are
directly targeted to and inserted into the MOM and/or the ER membrane (Bak, Bcl-xL and Bcl-2). In response to an apoptotic stimulus, BH3-only proteins
(yellow) translocate to interact with multidomain Bcl-2 family members on the MOM. Bim and Bmf dissociate from cytoskeletal structures, Bad from 14-3-3
and Bid is proteolytically cleaved. Bax and Bcl-w undergo a conformational change, which allows them to translocate and/or insert into the MOM.
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ing during apoptosis. However, these proteins may also
depend on chaperone proteins or their affinity for multido-
main Bcl-2 family members for efficient translocation [1].
2.1. Bax and Bcl-w: intra-molecular folding conceals the
mitochondrial signal sequence
The structures of the multidomain Bcl-2 family members
Bcl-xL, Bcl-2, Bcl-w and Bax closely resemble each other
despite their different roles in regulating the apoptotic process
[40,50–53]. As previously discussed, Bak and Bcl-2 consti-
tutively localize to the MOM and/or ER membrane where
they are inserted, whilst Bax and Bcl-w require regulatory
mechanisms which induce their translocation and insertion
into the MOM [19,22,54]. In non-apoptotic cells, Bax is
located in the cytosol and loosely attached to the MOM,
whilst Bcl-w is loosely attached to the MOM [38,55].
Whether MOM receptors or lipids mediate the loose attach-
ment of Bax and Bcl-w remains undefined. In response to
certain apoptotic stimuli, Bcl-w and Bax translocate and have
been suggested to insert into the MOM via their TMDs
[38,47,56,57]. Bcl-xL on the other hand is distributed be-
tween the cytosol and the MOM in different ratios, which
depend on the cell line analyzed [38,39,47].
The solution structures of Bcl-2 and Bcl-xL were deter-
mined in the absence of their C-terminal TMDs, as the
presence of these hydrophobic sequences would render
them insoluble [52,53]. This suggests that the TMDs of
these proteins may not be intra-molecularly folded, but
become exposed following synthesis and therefore require
chaperone-like molecules to prevent aggregation. These
chaperones may also guide Bcl-2 and Bcl-xL to their
respective membranes and be released upon association
with receptors on the target membrane. Bacterially synthe-
sized recombinant proteins may not contain these chaper-
ones and can therefore only be purified and crystallized in
high quantities when the hydrophobic C-terminal TMD is
removed [52,58]. In contrast, the structures of the soluble
forms of Bax and Bcl-w have revealed that their TMDs are
folded back into their hydrophobic pockets thereby increas-
ing the solubility of these proteins [40,50,51].
Bax is primarily located in the cytosol and loosely
attached to the MOM in non-apoptotic cells. In response
to an apoptotic stimulus, Bax has been suggested to undergo
a conformational change during which an N-terminal epi-
tope is revealed, the TMD is released and the hydrophobic
pocket becomes available for oligomerization [50,55,59,60].
Both the N- and the C-termini of Bax have been implicated
in its targeting to the MOM. Recently, an N-terminal
targeting sequence composed of amino acids 20–37 has
been reported as a targeting signal when fused to GFP [61].
However, deletion of the C-terminus of Bax prevents its
translocation, highlighting its importance as a targeting
sequence in this process [47,59]. Furthermore, our recent
data show that the last 23 aa of Bax, which constitute its
TMD, are necessary and sufficient to target Bax to the
MOM. In its cytosolic conformation, the TMD of Bax is
bound back into a hydrophobic pocket formed by its BH1,
BH2 and BH3 domains [50]. This conformation influences
the solubility of Bax by reducing its exposed hydrophobic
surface, preventing release of its TMD and exposure of the
hydrophobic pocket. Suzuki et al. [50] have reported that the
interactions between the pocket and the TMD are primarily
hydrophobic, except for a hydrogen bond, which is formed
between Asp98 in a-helix 4 and Ser184 in the TMD.
Mutation of Ser184 to Valine, Alanine or its deletion in a
GFP-Bax fusion protein causes Bax to become constitutive-
ly located on the mitochondria, suggesting that this interac-
tion plays an essential role in retaining the TMD in the
hydrophobic pocket [50,59].
The factors that initiate a conformational change in Bax
or cause its retention in the cytosol remain unknown. Suzuki
et al. [50] have suggested that the BH3 domain of other Bcl-
2 family members could not compete with the C-terminus of
Bax for the hydrophobic pocket and therefore an indepen-
dent energy-driven process would be required to disengage
the TMD. One possibility is that additional cytosolic pro-
teins bind to the TMD and act as a clamp to prevent its
release. A second possibility is that cytosolic binding
proteins associate with the N-terminus of Bax, which
somehow inhibit its conformational change. It has become
apparent that the N-terminus of Bax plays a role in its
retention in the cytosol. The structure of Bax shows that its
N-terminus is flexible and solvent-exposed; however, inside
cells, the N-terminal epitope of cytosolic Bax is not acces-
sible for antibody binding [39,50,59,62,63]. In this respect,
the N-terminus of Bax may act as an inhibitor of mitochon-
drial translocation. Indeed, removal of the N-terminal 20 aa
ART (apoptosis regulation of targeting) domain allows Bax
to be more effectively targeted to mitochondria [56,64].
Furthermore, it has been reported that the N-terminal
cleavage of Bax by calpain results in the generation of a
highly apoptogenic 18-kDa fragment [65–68]. Therefore,
the binding proteins associated with the N- or C-termini of
Bax would have to be degraded or released before the TMD
can be released from the hydrophobic pocket.
Several candidate proteins, which may assume this role,
have recently been described. Cuddeback et al. [69] have
reported that Bif (Bax-interacting factor) promotes the trans-
location of Bax from the cytosol to the mitochondria fol-
lowing an apoptotic stimulus possibly by inducing a
conformational change in Bax. However, the exact molecu-
lar mechanism causing this event remains undefined. Fur-
thermore, Nomura et al. [70] have recently proposed that the
cytosolic chaperone 14-3-3 interacts with Bax. Interestingly,
they have reported that the protein makes contacts with the
N- and C-termini of Bax and therefore may act as a bridge
between these extremities. This would not only prevent the
TMD from being released, but also prevent a change in the
cytosolic conformation of Bax, which may be reflected by
the opening and accessibility of its N-terminus. How would
N-terminal opening be initiated inside cells? The 14-3-3
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protein is cleaved by a caspase in apoptotic cells, releases
Bax and may initiate N-terminal opening and release of the
TMD. Recently, Sawada et al. [71] have found that Ku70, a
protein known so far for its function in DNA repair within
the nucleus, binds to the N-terminus of cytosolic Bax and
prevents its translocation to mitochondria following staur-
osporine or UVC treatment. A peptide of 5 aa encompassing
the binding domain in Ku70 has a similar inhibitory effect
[72]. The mechanism by which Ku70 is thought to act is by
inhibiting N-terminal opening and thereby preventing con-
formational change. However, the forced dissociation of
Ku70 is not sufficient to activate Bax, suggesting that
another event is required to make Bax competent for mito-
chondrial translocation [71]. Another cytosolic retention
factor, which has recently been described, is the peptide
Humanin. Humanin binds to the C-terminus of Bax and has
been shown to prevent Bax translocation following trans-
fection into human cells [73]. However, as for Ku70,
reducing endogenous levels of Humanin only sensitized
cells to apoptotic stimuli, and therefore a secondary step
would be required for the activation of Bax [73].
Two recent reports have described the structure of Bcl-
w [40,51]. The C-terminus of Bcl-w, like that of Bax, is
folded back into a hydrophobic pocket giving it the attrib-
utes of a compact globular molecule. Bcl-w is found loosely
attached to mitochondria in healthy cells and becomes
integrated into the MOM in response to an apoptotic
stimulus [38,40,51]. Like Bax, Bcl-w has been suggested
to undergo a conformational change, during which its C-
terminal helix is displaced from the pocket, allowing the
insertion of Bcl-w into the MOM [40,51]. The intra-molec-
ular interactions between the C-terminus and the hydropho-
bic pocket in Bcl-w appear to be weaker than in Bax,
making its C-terminus more mobile than that of Bax.
However, the C-terminus still restricts access to the hydro-
phobic pocket as truncation of the C-terminus of Bcl-
w resulted in a higher affinity of certain BH3-only proteins
for Bcl-w [40,51]. Therefore, contrary to the suggestions
made for Bax, BH3-only proteins appear to be able to
displace the C-terminus of Bcl-w from the hydrophobic
groove without any additional energetic input [50,51].
Hinds et al. [40] have shown that Bim and Bmf can bind
to Bcl-w and that a conserved leucine residue in their BH3
domains may be necessary for the displacement of the C-
terminus from the hydrophobic pocket. A similar mecha-
nism in which the C-terminus restricts access to the hydro-
phobic pocket has been suggested to occur in Bcl-xL [40].
2.2. BH3-onlies: subcellular localization mediated by
posttranslational modification
As the sensors of apoptotic stress, BH3-only proteins are
sequestered in the cytoplasm, but are suggested to function in
association with the multidomain Bcl-2 family members,
which are located predominantly on the MOM, ER mem-
brane and its associated nuclear envelope. Certain BH3-only
proteins including Noxa, Puma/Bbc3, Bim, Hrk/Dp5 are
transcriptionally induced in response to apoptotic stimuli;
whilst others, including Bid, Bim, Bmf and Bad, have been
reported to be posttranslationally modified and/or proteolyt-
ically processed in response to apoptotic stimuli [2,48,49].
These modifications may induce the exposure of targeting
sequences, allow for interactions with chaperones and/or
increase the affinity of BH3-only proteins for multidomain
Bcl-2 family members. Although some BH3-only proteins
bind to multidomain Bcl-2 family members with high affinity
and may therefore be attached to the MOM and ER mem-
brane via these proteins, others such as Bik, Hrk, Blk, Bim,
and Bim contain their own C-terminal TMD regions. As for
Bax and Bcl-w, the TMDs of these BH3-only proteins may be
unavailable in healthy cells and only become available for
targeting in response to an apoptotic stimulus [1].
2.2.1. Bid
In healthy cells Bid is located in the cytosol in an inactive
form. In response to death receptor activation, Bid is
cleaved by caspase-8 to form truncated Bid (tBid). tBid
can then translocate to the mitochondria to interact with
multidomain Bcl-2 family members [74–76]. Targeting of
tBid to the mitochondria following proteolytic cleavage is
facilitated by posttranslational N-myristoylation of a glycine
residue, which becomes exposed following the cleavage of
Bid by caspase-8 [77]. Furthermore, Bid has been reported
to be targeted to the mitochondria via its high affinity for the
lipid cardiolipin [78,79]. The phosphorylation of Bid by
casein kinases I and II has been reported to prevent its
translocation. This phosphorylation event occurs in the
vicinity of the recognition site for caspase-8 and consequen-
tially renders Bid resistant to cleavage [76]. Granzyme B
has also been reported to cleave Bid to generate a 14-kDa
granzyme-truncated Bid (gtBid), which translocates to mi-
tochondria and associates with Bax [80].
2.2.2. Bad
In vitro and in cell culture, Bad is regulated by a variety
of survival promoting kinases, which phosphorylate it on
multiple serine residues. The phosphorylation of these
residues promotes its interaction with 14-3-3 scaffold pro-
teins and its sequestration in the cytosol [81–84]. Several
kinases have been reported to phosphorylate Bad on serines
112 and 135. These include: AKT/PKB, which is a trans-
ducer of survival signals of growth factors within the PI3-
kinase pathway, and Raf-1, which couples growth factor
receptors to the MAPK pathway. [81,82,85]. PKA phos-
phorylates serine 155 of Bad, which is located in its BH3
domain. This phosphorylation event has been reported to
decrease the affinity of Bad for Bcl-2 [83,86]. The impor-
tance of Bad phosphorylation has been emphasized by the
phenotype of Bad ‘knock-in’ mice, which express a consti-
tutively active Bad mutant, in which serine residues at
positions 112, 136 and 155 are replaced by alanines. These
mice display no obvious abnormalities but are hypersensi-
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tive to a variety of apoptotic stresses [87]. The kinases
responsible for the phosphorylation of Bad are located both
in the cytosol and on the mitochondria. The mechanisms by
which Bad is phosphorylated by mitochondrial kinases
without associating with Bcl-2 family members has not
been defined. In a recent review, Puthalakath and Strasser
[49] have suggested that Bad may either have a higher
affinity for these kinases than for Bcl-2 family members or
may rely on chaperone proteins to guide it to Bcl-xL, its
putative binding partner on the MOM. Growth factor
withdrawal has been shown to lead to the dephosphorylation
of Bad and its dissociation from 14-3-3, hence promoting its
pro-apoptotic activity by its association with Bcl-xL [88]. In
calcium-induced apoptosis, calcineurin has been shown to
dephosphorylate Bad allowing its translocation and interac-
tion with Bcl-xL [89]. Other events have also been sug-
gested to lead to the disassociation of Bad from 14-3-3, for
example, the cleavage of 14-3-3 by caspase-3 has been
reported to facilitate Bad activation [90].
2.2.3. Bim and Bmf
In healthy cells, Bim and Bmf are bound to cytoskeletal
structures. In response to an apoptotic stimulus, these
proteins are released and translocate to interact with multi-
domain Bcl-2 family members on the mitochondria [91]. As
well as being transcriptionally regulated, Bim is also regu-
lated by alternative splicing during which three major iso-
forms are formed, BimEL, BimL and BimS [92]. BimEL and
BimL have been shown to bind to DLC1/LC8 of the
microtubular dynein motor complex [91]. Treatment with
taxol, cytokine deprivation and abnormal calcium flux
induce the dissociation of BimL, still bound to DLC-1/L8,
from the dynein motor complex. This dissociation event
allows BimL to translocate to the MOM, ER membrane and
its associated nuclear envelope where it interacts with Bcl-2
family members [91,93]. Little is known about the mecha-
nisms by which Bim translocates, although enzymes such as
CDK5, which are known to affect the dynein motor func-
tion, have been suggested [94,95]. Withdrawal of NGF has
also been shown to promote Bim phosphorylation mediated
by the MAPK pathway, possibly regulating the association
of Bim with an unknown partner [96]. Bmf is bound to
DLC2 on the actin cytoskeleton-based myosin V motor
complex in healthy cells and translocates to the mitochon-
dria to bind Bcl-2 family members in response to apoptotic
stimuli such as anoikis and actin depolymerising drugs
[49,94]. Upon exposure to environmental stress, JNK has
been suggested to phosphorylate both Bim and Bmf causing
their release from the dynein motor complexes [96].
3. Conclusions and perspectives
Members of the Bcl-2 family are crucial regulators of
apoptosis, which are located on different intracellular mem-
branes and activated by a variety of different mechanisms.
Table 1
Overview on the intracellular localizations, translocations and posttranslational modifications of some Bcl-2 family members
Bcl-2
Family
Member
COOH-terminal
TMD
Localization in
healthy cells
Localization in
apoptotic cells
Binding proteins
or receptors in
healthy cells
Binding proteins
or receptors in
apoptotic cells
Posttranslational
modification
Bcl-2 Yes MOM-, ER-, nuclear
envelope inserted
MOM-, ER-, nuclear
envelope inserted
FKB38, BAP-31,
Pro-apoptotic,
Bax-like proteins
(Bax, Bak) ?
BH3-onlies, others? ?
Mcl-1 Yes MOM-, ER-, nuclear
envelope inserted (?)
MOM-, ER-, nuclear
envelope inserted (?)
Pro-apoptotic,
Bax-like proteins
(Bax, Bak) ?
BH3-onlies, others? ?
Bcl-xL Yes Cytosolic,
MOM-inserted
and loosely attached
MOM-inserted FKBP38, Pro-apoptotic,
Bax-like proteins
(Bax, Bak) ?
BH3-onlies others? Conformational
change (?)
Bcl-w Yes MOM—loosely
attached
MOM-inserted Pro-apoptotic,
Bax-like proteins
(Bax, Bak)
BH3-onlies others? Conformational
change
Bax Yes Cytosolic, ER and
MOM—loosely
attached
MOM-inserted,
ER-inserted (?)
14-3-3, Bif-1, Ku70,
humanin
tBid (transient
interaction ?)
Conformational
change
Bak Yes MOM-, ER-inserted MOM-inserted,
ER-inserted (?)
? tBid (transient
interaction ?)
?
Bad No Cytosolic MOM 14-3-3 Bcl-xL Phophorylation
Bid No Cytosolic MOM ? Bax, Bak (transient
interaction ?)
Proteolytic processing,
phosphorylation,
myristoylation
Bim/Bod Yes DLC1-associated
(microtubules)
MOM inserted ? DLC1 Anti-apoptotic Bcl-2
family members
Phophorylation
Bmf No DLC-2 associated
(myosinV/actin-cytoskeleton)
MOM inserted ? DLC2 Anti-apoptotic Bcl-2
family members
Phophorylation
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An overview of some of their features is given in Table 1. It
has become increasingly clear that the multidomain mem-
bers of the Bcl-2 family carry a COOH-terminal TMD and
therefore behave like other tail-anchored proteins. In con-
trast to the ‘classical’ membrane insertion pathways, the
research describing the targeting and insertion of tail-an-
chored proteins is recent and the details of these mecha-
nisms remain undefined. Following synthesis, tail-anchored
proteins are targeted either to the ER membrane and its
associated nuclear envelope or to the MOM where the TMD
becomes inserted in a stable fashion and the bulk of the
protein faces the cytosol. Membrane-bound receptors appear
to be involved in this process, and it may eventually become
evident that some of the receptors and mechanisms required
for ‘classical’ insertion or translocation pathways may also
play a role in tail-anchoring.
The sequences and chaperones necessary for intracellular
targeting, the mechanism of activation and the exact func-
tion of many individual Bcl-2 family members in promoting
or preventing apoptosis remain to be defined. The majority
of studies, which have defined the subcellular location,
targeting sequences, modifications and interactions of these
proteins, have been performed in vitro or in cell culture
models, often using fusion proteins or overexpressed wild-
type proteins. However, little is known about whether these
proteins are indeed targeted to and have specific functions
on particular intracellular organelles in tissues of multicel-
lular organisms. It remains to be determined whether these
events are of physiological relevance. For example, does
Bcl-2, which is reported to reside to a major extent on the
ER membrane, have an ER-specific function? Is Bcl-xL only
functional when it resides on the MOM? What influence do
chaperone proteins have on the subcellular distribution of
Bcl-2 and Bcl-xL? Are these two proteins equally distributed
throughout the various tissues of an organism? Do the low
levels of Bax and Bak located on the ER membrane control
membrane permeability of the ER in a similar way as they
do on the MOM? Or is there an alternative ER-specific
function for these proteins?
There is little evidence describing the mechanisms by
which BH3-only proteins, which do not have a TMD, reach
and remain on the appropriate intracellular membrane in
response to apoptotic stimuli. One possibility is that BH3-
only proteins interact with multidomain Bcl-2 family mem-
bers, which are already present on the MOM or the ER
membrane at the time of their activation. It appears that
BH3-only proteins interact with antiapoptotic proteins such
as Bcl-2 and Bcl-xL, neutralizing their antiapoptotic func-
tion. The only known exception so far is tBid, which has
been shown to favor the binding to and activation of
proapoptotic Bax and Bak. It may also be possible that
BH3-only proteins bind to unknown proteins on the MOM
and ER-membranes and this could very well be the case for
multidomain Bcl-2 family members as well.
Bcl-2 family members, which are sequestered in the
cytosol or on intracellular structures and are not directly
targeted to the membrane on which they function, require
secondary mechanisms of regulation for their translocation.
These posttranslational mechanismsmay be dependent on the
apoptotic stress and cell type. Therefore, in different tissues
distinct posttranslational mechanisms could activate specific
Bcl-2 family members in response to various apoptotic stim-
uli. Generation of mice in which one or more Bcl-2 family
members have been ‘knocked out’, conditional and tissue-
specific knockouts as well as ‘knock in’ mice will provide
further insight into the role of posttranslational mechanisms
in the activation of Bcl-2 family members in vivo.
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